Current Studies
Please get in touch with our Research department for further information regarding participating in a clinical trial. Lake Cumberland Rheumatology’s Research department can be reached by email at [email protected] or by phone by dialing (502) 351-6983.
The LC Rheumatology staff that are a part of the research team include:
Coordinators: Lisa Boone, RN, BSN, CCRC, Research Manager and Kara Lay
Primary Investigators: Scott Lewis, DO and Tmothy Lonesky, DO
Sub-Investigators: Natalie Lane, APRN, Dana Mann, APRN, and Charles Moore, MD
Research Assistant: Amanda Conrad
Research Assistant: Amanda Conrad
A Randomized, Double-Blind, Placebo-Controlled Phase 4 Clinical Trial to Evaluate the Long-Term Safety and Efficacy of Avacopan in Subjects With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
Sponsor: AMGEN
Participants must be:
- 18 years of age or older, newly diagnosed or relapse of granulomatosis with polyangiitis or microscopic polyangiitis
- starting treatment with cyclophosphamide or rituximab
A Study to Investigate Effectiveness of Tirzepatide in Clinical Practice following Initiation of Ixekizumab in Participants with Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
Sponsor: ELI LILLY
Participants must be:
- 18 years or older, diagnosed with Psoriatic Arthritis.
- BMI of 30 and treated with Taltz for 3 months, able to start Zepbound (cannot have any prior exposure to Zepbound/Mounjaro/Wegovy/Trulicity/Victoza)
A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of dapirolizumab pegol in study participants with moderately to severely active systemic lupus erythematosus (PHOENYCS FLY)
Sponsor: UCB
Participants must be:
-
18 years of age or older, diagnosed with Systemic Lupus Erythematosus for at least 6 months
-
having symptoms or flare on current oral anti-malarial/DMARD/corticosteroid therapy, and ready to start a biologic medication
Systemic Lupus Erythematosus (SLE) Drug Safety and Effectiveness Registry (SLE-800) and Biorepository (BIO-800)
Sponsor: CorEvitas
Participants must be:
-
18 years or older, diagnosed Systemic Lupus Erythematosus
-
currently a LCR patient, willing to provide blood samples
Multinational, Interventional, 52-Week, Open-Label, Single-arm Study to Evaluate the Treatment Outcomes of Anifrolumab 120mg Subcutaneous Once Weekly in Immunosuppressant-Naïve and biologic-Naïve Systemic Lupus Ertythematosus (SUNFLOWER)
Sponsor: ASTRAZENECA
Participants must be:
- 18 to 70 years of age, diagnosed with Systemic Lupus Erythematosus for at least 3 months before screening
- having symptoms or flare on current oral anti-malarial (Plaquenil) medication and ready to start a biologic medication
